FDAnews
www.fdanews.com/articles/81173-octoplus-and-singvax-announce-collaboration-to-develop-single-shot-japanese-encephalitis-vaccine

OCTOPLUS AND SINGVAX ANNOUNCE COLLABORATION TO DEVELOP SINGLE-SHOT JAPANESE ENCEPHALITIS VACCINE

September 26, 2005

OctoPlus, the Dutch drug delivery and development company, and SingVax Pte Ltd, a Singapore-based vaccine development company, today announced their collaboration to co-develop a single-shot Japanese encephalitis (JE) vaccine. Existing JE vaccines typically require two or three doses. By creating a single-shot JE vaccine the companies aim to achieve increased patient compliance and greater efficacy of the vaccine. As such, it will help protect more people from this life threatening disease. OctoPlus and SingVax target a significant proportion of the estimated US$400 million global market for JE vaccines.

PR Newswire UK (http://www.prnewswire.co.uk/cgi/news/release?id=154496)